Original language | English (US) |
---|---|
Pages (from-to) | 2093-2110 |
Number of pages | 18 |
Journal | Annals of Thoracic Surgery |
Volume | 93 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2012 |
ASJC Scopus subject areas
- Surgery
- Pulmonary and Respiratory Medicine
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Annals of Thoracic Surgery, Vol. 93, No. 6, 06.2012, p. 2093-2110.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Multisociety (AATS, ACCF, SCAI, and STS) Expert Consensus Statement
T2 - Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement, Part 1: Transcatheter Aortic Valve Replacement
AU - Tommaso, Carl L.
AU - Bolman, R. Morton
AU - Feldman, Ted
AU - Bavaria, Joseph
AU - Acker, Michael A.
AU - Aldea, Gabriel
AU - Cameron, Duke E.
AU - Dean, Larry S.
AU - Fullerton, Dave
AU - Hijazi, Ziyad M.
AU - Horlick, Eric
AU - Miller, D. Craig
AU - Moon, Marc R.
AU - Ringel, Richard
AU - Ruiz, Carlos E.
AU - Trento, Alfredo
AU - Weiner, Bonnie H.
AU - Zahn, Evan M.
N1 - Funding Information: The granting of staff privileges to physicians is an important mechanism to ensure quality care. The Joint Commission on Accreditation of Healthcare Organizations requires that medical staff privileges be based on professional criteria specified in medical staff bylaws. Physicians are charged with defining the criteria that constitute professional competence and with evaluating their peers accordingly. With the evolution of transcatheter aortic valve replacement (TAVR), an important opportunity arises for both cardiologists and surgeons to come together to identify the criteria for performing these procedures. The Society for Cardiovascular Angiography and Interventions (SCAI), American Association for Thoracic Surgery (AATS), American College of Cardiology Foundation (ACCF), and The Society of Thoracic Surgeons (STS) have, therefore, joined together to provide recommendations for institutions to assess their potential for instituting and/or maintaining a transcatheter valve program. This article concerns TAVR. As TAVR is in its infancy, there are few data on which to base this consensus statement. Therefore, many of these recommendations are based on expert consensus. As the procedures evolve, technology changes, experience grows, and more data is accumulated, there will certainly be a need to update this consensus statement. However, with the Food and Drug Administration (FDA) having just approved the first generation of TAVR devices, the writing committee and participating societies believe that the recommendations listed in this report serve as an appropriate starting point. In some ways, these recommendations apply to institutions more than to individuals. As there is a strong consensus that these new valve therapies are best performed using a team approach, these credentialing criteria may be best applied at the institutional level. Partnering societies used the ACCF's policy on relationships with industry and other entities (RWI) to author this document ( http://www.cardiosource.org/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/Relationships-With-Industry-Policy.aspx ). To avoid actual, potential, or perceived conflicts of interest that may arise as a result of industry relationships or personal interests among the writing committee, all members of the writing committee, as well as peer reviewers of the document, were asked to disclose all current healthcare-related relationships, including those existing 12 months before initiation of the writing effort. A committee of interventional cardiologists and surgeons was formed to include a majority of members with no relevant RWI and be led by an interventional cardiology co-chair and a surgical co-chair with no relevant RWI. Authors with relevant RWI were not permitted to draft or vote on text or recommendations pertaining to their RWI. RWI were reviewed on all conference calls and updated as changes occurred. Author and peer reviewer RWI pertinent to this document are disclosed in Appendices 1 and 2 , respectively. In addition, to ensure complete transparency, authors' comprehensive disclosure information (including RWI not pertinent to this document) is available as an online supplement to this document at http://content.onlinejacc.org/cgi/content/full/j.jacc.2012.02.016/DC1 . The work of the writing committee was supported exclusively by the partnering societies without commercial support. Writing committee members volunteered their time to this effort. Conference calls of the writing committee were confidential and attended only by committee members. SCAI, AATS, ACCF, and STS believe that adherence to these recommendations will maximize the chances that these therapies will become a successful part of the armamentarium for treating valvular heart disease in the United States. In addition, these recommendations will hopefully facilitate optimum quality during the delivery of this therapy, which will be important to the development and successful implementation of future, less invasive approaches to structural heart disease.
PY - 2012/6
Y1 - 2012/6
UR - http://www.scopus.com/inward/record.url?scp=84861586111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861586111&partnerID=8YFLogxK
U2 - 10.1016/j.athoracsur.2012.02.063
DO - 10.1016/j.athoracsur.2012.02.063
M3 - Article
C2 - 22386085
AN - SCOPUS:84861586111
SN - 0003-4975
VL - 93
SP - 2093
EP - 2110
JO - Annals of Thoracic Surgery
JF - Annals of Thoracic Surgery
IS - 6
ER -